Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 33, Issue 3, 2010, Pages 217-220

  La Vine, David B T ^a   Coleman, Teresa A ^a   Davis, Carol H ^a   Carbonell, Christine E ^a   Davis, Wendy B ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Renal cell carcinoma; Reverse tyrosine kinase inhibitors; Sorafenib; Sunitinib; Toxicities

Indexed keywords

PHOSPHOTRANSFERASE INHIBITOR; SORAFENIB; SUNITINIB;

ADULT; ADVANCED CANCER; ARTICLE; CANCER CONTROL; CANCER SURVIVAL; CLINICAL ARTICLE; DIARRHEA; DISEASE COURSE; DIZZINESS; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN TISSUE; HYPERTENSION; HYPOTHYROIDISM; KIDNEY CARCINOMA; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SKIN TOXICITY; SURVIVAL TIME; TREATMENT DURATION; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, RENAL CELL; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; DRUG ERUPTIONS; FEMALE; HUMANS; HYPERTENSION; HYPOTHYROIDISM; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PYRIDINES; PYRROLES; RETROSPECTIVE STUDIES;

EID: 77953345705     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3181a650a6     Document Type: Article

References (16)

1. Jemal A, Siegel R, Eard E, et al. Cancer statsitics 2008. CA Cancer J Clin. 2008;58:71-96.
2. Cohen H, McGovern F. Renal cell carcinoma. N Engl J Med. 2005;353:2477-2490.
3. Coppin C, Porzsolt F, Awa A, et al. Immunotherapy for advanced renal cell carcinoma. Cochrane Database Syst Rev. 2005;1:CD001425.
4. Choueiri TK, Plantade A, Elson P, et al. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol. 2008;26:127-131.
5. Patel PH, Chaganti RSK, Motzer RJ. Targeted therapy for metastatic renal cell carcinoma. Br J Cancer. 2006;94:614-619.
6. Escudier B, Eisen T, Stadler W, et al. Sorafenib in advanced clear cell renal cell carcinoma. N Engl J Med. 2007;356:125-134. (Pubitemid 46089673)
7. Ratain MJ, Stadler WM, Flaherty KT, et al. Phase II placebo-controlled randomized discontinuation trial of Sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24:2505-2512.
8. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal cell carcinoma. N Engl J Med. 2007;356:115-124.
9. Riechelmann RP, Chin S, Wang L, et al. Sorafenib for metastatic renal cell carcinoma, the Princess Margaret experience. Am J Clin Oncol. 2008;31:182-187.
10. Chu D, Lacouture ME, Filllos T, et al. Risk of hand foot skin reaction with sorafenib: a systemic review and meta-analysis. Acta Oncol. 2008;47:176-186.
11. Van der Veldt, Boven E, Helgason HH, et al. Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer. Br J Cancer. 2008;1-7.
12. Moore M, Hirte HW, Siu L, et al. Phase I study to determine the safety and pharmacokinetic study of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7days off in patients with advanced refractory solid tumors. Ann Oncol. 2005;16:1688-1694.
13. Awasa A, Hendliz A, Gil T, et al. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumors. Br J Cancer. 2005;92:1855-1861.
14. Clark JW, Elders JP, Ryan D, et al. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res. 2005;11:5472-5480.
15. Fiavre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol. 2006;24:25-35.
16. Amato RJ, Harris P, Dalton M, et al. A phase II trial of intra-patient dose-escalated sorafenib in patients with metastatic renal cell carcinoma[Abstract 5107]. J Clin Oncol. 2007;25:18S.